Article

You have full text access to this OnlineOpen article

The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues

  1. Weng Chuan Peng,
  2. Xin Lin,
  3. Jaume Torres*

Article first published online: 11 JAN 2009

DOI: 10.1002/pro.65

Issue

Protein Science

Protein Science

Volume 18, Issue 2, pages 450–459, February 2009

Additional Information

How to Cite

Peng, W. C., Lin, X. and Torres, J. (2009), The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues. Protein Science, 18: 450–459. doi: 10.1002/pro.65

Author Information

  1. School of Biological Sciences, Nanyang Technological University, Singapore

*School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551

Publication History

  1. Issue published online: 30 JAN 2009
  2. Article first published online: 11 JAN 2009
  3. Accepted manuscript online: 11 JAN 2009 12:00AM EST
  4. Manuscript Accepted: 1 DEC 2008
  5. Manuscript Revised: 17 NOV 2008
  6. Manuscript Received: 30 AUG 2008

Funded by

  • Biomedical Research Council (BMRC) of Singapore. Grant Number: 04/1/22/19/361

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (352K)

References

  • 1
    Schlessinger J ( 2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211–225.
  • 2
    Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J ( 1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276: 955–960.
  • 3
    Hubbard SR, Mohammadi M, Schlessinger J ( 1998) Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998; 273: 11987–11990.
  • 4
    Mendrola JM, Berger MB, King MC, Lemmon MA ( 2002) The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem 277: 4704–4712.
  • 5
    Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Cremel G, Hubert P ( 2004) Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell 15: 3464–3474.
  • 6
    Bell CA, Tynan JA, Hart KC, Meyer AN, Robertson SC, Donoghue DJ ( 2000) Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. Mol Biol Cell 11: 3589–3599.
  • 7
    Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, You Y, Liu KD, Goldsmith MA, He W, Krause CD, Pestka S, Jolliffe LK, Wilson IA ( 1998) An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol 5: 993–1004.
  • 8
    Adar R, Monsonego-Ornan E, David P, Yayon A ( 2002) Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J Bone Miner Res 17: 860–868.
    Direct Link:
  • 9
    Li E, Hristova K ( 2006) Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 45: 6241–6251.
  • 10
    Massague J, Pilch PF, Czech MP ( 1981) A unique proteolytic cleavage site on the beta subunit of the insulin receptor. J Biol Chem 256: 3182–3190.
  • 11
    Luo RZ, Beniac DR, Fernandes A, Yip CC, Ottensmeyer FP ( 1999) Quaternary structure of the insulin-insulin receptor complex. Science 285: 1077–1080.
  • 12
    Hynes RO ( 2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673–687.
  • 13
    Muenke M, Schell U ( 1995) Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 11: 308–313.
  • 14
    Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A ( 1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371: 252–254.
  • 15
    Tavormina PL, Rimoin DL, Cohn DH, Zhu YZ, Shiang R, Wasmuth JJ ( 1995) Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol Genet 4: 2175–2177.
  • 16
    Rousseau F, el Ghouzzi V, Delezoide AL, Legeai-Mallet L, Le Merrer M, Munnich A, Bonaventure J ( 1996) Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet 5: 509–512.
  • 17
    Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW ( 1995) Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 11: 462–464.
  • 18
    Otsuki T, Nakazawa N, Taniwaki M, Yamada O, Sakaguchi H, Wada H, Yawata Y, Ueki A ( 1998) Establishment of a new human myeloma cell line, KMS-18, having t(4;14)(p16.3;q32.3) derived from a case phenotypically transformed from Ig A-lambda to BJP-lambda, and associated with hyperammonemia. Int J Oncol 12: 545–552.
  • 19
    van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, van der Kwast TH, Zwarthoff EC, Radvanyi F ( 2002) Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 10: 819–824.
  • 20
    Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I, Wang H, Imyanitov E, Haring HU, Knayzev P, Iacobelli S, Hofler H, Ullrich A ( 2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62: 840–847.
  • 21
    Li E, You M, Hristova K ( 2006) FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J Mol Biol 356: 600–612.
  • 22
    Smith SO, Smith CS, Bormann BJ ( 1996) Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor. Nat Struct Biol 3: 252–258.
  • 23
    Smith SO, Smith C, Shekar S, Peersen O, Ziliox M, Aimoto S ( 2002) Transmembrane interactions in the activation of the Neu receptor tyrosine kinase. Biochemistry 41: 9321–9332.
  • 24
    Webster MK, Donoghue DJ ( 1996) Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. Embo J 15: 520–527.
  • 25
    Monsonego-Ornan E, Adar R, Feferman T, Segev O, Yayon A ( 2000) The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 20: 516–522.
  • 26
    Cho JY, Guo C, Torello M, Lunstrum GP, Iwata T, Deng C, Horton WA ( 2004) Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 101: 609–614.
  • 27
    You M, Li E, Hristova K ( 2006) The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain. Biochemistry 45: 5551–5556.
  • 28
    Luo BH, Springer TA, Takagi J ( 2004) A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol 2: 776–786.
  • 29
    Schneider D, Engelman DM ( 2004) Involvement of transmembrane domain interactions in signal transduction by α/β integrins. J Biol Chem 279: 9840–9846.
  • 30
    Li E, You M, Hristova K ( 2005) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and forster resonance energy transfer suggest weak interactions between fibroblast growth factor receptor 3 (FGFR3) transmembrane domains in the absence of extracellular domains and ligands. Biochemistry 44: 352–360.
  • 31
    Stanley AM, Fleming KG ( 2005) The transmembrane domains of ErbB receptors do not dimerize strongly in micelles. J Mol Biol 347: 759–772.
  • 32
    Arkin IT, MacKenzie KR, Brunger AT ( 1997) Site-directed dichroism as a method for obtaining rotational and orientational constraints for oriented polymers. J Am Chem Soc 119: 8973–8980.
  • 33
    Kukol A, Adams PD, Rice LM, Brunger AT, Arkin TI ( 1999) Experimentally based orientational refinement of membrane protein models: a structure for the Influenza A M2 H+ channel. J Mol Biol 286: 951–962.
  • 34
    Torres J, Adams PD, Arkin IT ( 2000) Use of a new label, 13C[DOUBLE BOND]18O, in the determination of a structural model of phospholamban in a lipid bilayer. Spatial restraints resolve the ambiguity arising from interpretations of mutagenesis data. J Mol Biol 300: 677–685.
  • 35
    Torres J, Parthasarathy K, Lin X, Saravanan R, Kukol A, Liu DX ( 2006) Model of a putative pore: the pentameric α-helical bundle of SARS coronavirus E protein in lipid bilayers. Biophys J 91: 938–947.
  • 36
    Parthasarathy K, Ng L, Lin X, Liu DX, Pervushin K, Gong X, Torres J ( 2008) Structural flexibility of the pentameric SARS coronavirus envelope protein ion channel. Biophys J 95: L39–L41.
  • 37
    Torres J, Kukol A, Goodman JM, Arkin IT ( 2001) Site-specific examination of secondary structure and orientation determination in membrane proteins: the peptidic 13C[DOUBLE BOND]18O group as a novel infrared probe. Biopolymers 59: 396–401.
    Direct Link:
  • 38
    Beevers AJ, Kukol A ( 2006) Secondary structure, orientation, and oligomerization of phospholemman, a cardiac transmembrane protein. Protein Sci 15: 1127–1132.
    Direct Link:
  • 39
    Gan SW, Ng L, Xin L, Gong X, Torres J ( 2008) Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Protein Sci 17: 813–820.
    Direct Link:
  • 40
    Kochendoerfer GG, Salom D, Lear JD, Wilk-Orescan R, Kent SB, DeGrado WF ( 1999) Total chemical synthesis of the integral membrane protein influenza A virus M2: role of its C-terminal domain in tetramer assembly 1. Biochemistry 38: 11905–11913.
  • 41
    Fleming KG ( 2002) Standardizing the free energy change of transmembrane helix-helix interactions. J Mol Biol 323: 563–571.
  • 42
    Cristian L, Lear JD, DeGrado WF ( 2003) Use of thiol-disulfide equilibria to measure the energetics of assembly of transmembrane helices in phospholipid bilayers. Proc Natl Acad Sci USA 100: 14772–14777.
  • 43
    Stouffer AL, Ma C, Cristian L, Ohigashi Y, Lamb RA, Lear JD, Pinto LH, DeGrado WF ( 2008) The interplay of functional tuning, drug resistance, and thermodynamic stability in the evolution of the M2 proton channel from the influenza A virus. Structure 16: 1067–1076.
  • 44
    Briggs JAG, Torres J, Arkin IT ( 2001) A new method to model membrane protein structure based on silent amino acid substitutions. Proteins 44: 370–375.
    Direct Link:
  • 45
    Byler DM, Susi H ( 1986) Examination of the secondary structure of proteins by deconvolved FTIR spectra. Biopolymers 25: 469–487.
    Direct Link:
  • 46
    Torres J, Briggs JA, Arkin IT ( 2002) Multiple site-specific infrared dichroism of CD3-z, a transmembrane helix bundle. J Mol Biol 316: 365–374.
  • 47
    You M, Spangler J, Li E, Han X, Ghosh P, Hristova K ( 2007) Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers. Biochemistry 46: 11039–11046.
  • 48
    Doura AK, Kobus FJ, Dubrovsky L, Hibbard E, Fleming KG ( 2004) Sequence context modulates the stability of a GxxxG-mediated transmembrane helix-helix dimer. J Mol Biol 341: 991–998.
  • 49
    Fisher LE, Engelman DM, Sturgis JN ( 2003) Effect of detergents on the association of the glycophorin a transmembrane helix. Biophys J 85: 3097–3105.
  • 50
    Fleming KG, Ren CC, Doura AK, Eisley ME, Kobus FJ, Stanley AM ( 2004) Thermodynamics of glycophorin A transmembrane helix dimerization in C14 betaine micelles. Biophys Chem 108: 43–49.
  • 51
    Stouffer AL, Nanda V, Lear JD, DeGrado WF ( 2005) Sequence determinants of a transmembrane proton channel: an inverse relationship between stability and function. J Mol Biol 347: 169–179.
  • 52
    Stouffer AL, DeGrado WF, Lear JD ( 2006) Analytical ultracentrifugation Studies of the Influenza M2 homotetramerization equilibrium in detergent solutions. Progr Colloid Polym Sci 131: 108–115.
  • 53
    Li RH, Mitra N, Gratkowski H, Vilaire G, Litvinov R, Nagasami C, Weisel JW, Lear JD, DeGrado WF, Bennett JS ( 2003) Activation of integrin αIIbβ3 by modulation of transmembrane helix associations. Science 300: 795–798.
  • 54
    Gerber D, Sal-Man N, Shai Y ( 2004) Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization. J Biol Chem 279: 21177–21182.
  • 55
    Vajo Z, Francomano CA, Wilkin DJ ( 2000) The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 21: 23–39.
  • 56
    Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ ( 1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78: 335–342.
  • 57
    Wellings DA, Atherton E ( 1997) Standard Fmoc protocols. Methods Enzymol 289: 44–67.
  • 58
    Iwamoto T, You M, Li E, Spangler J, Tomich JM, Hristova K ( 2005) Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications. Biochim Biophys Acta 1668: 240–247.
  • 59
    Ramjeesingh M, Huan LJ, Garami E, Bear CE ( 1999) Novel method for evaluation of the oligomeric structure of membrane proteins. Biochem J 342 (Part 1): 119–123.
  • 60
    Li R, Babu CR, Lear JD, Wand AJ, Bennett JS, DeGrado WF ( 2001) Oligomerization of the integrin αIIbβ3: roles of the transmembrane and cytoplasmic domains. Proc Nat Sci USA 98: 12462–12467.
  • 61
    Demeler B ( 2005) UltraScan, a comprehensive data analysis software package for analytical ultracentrifuge experiments. In: ScottDJ, HardingSE, RoweAJ, Eds. Modern analytical ultracentrifugation: techniques and methods. Royal Society of Chemistry (UK), pp 210–229.
  • 62
    Laue TM, Stafford WF,III ( 1999) Modern applications of analytical ultracentrifugation. Annu Rev Biophys Biomol Struct 28: 75–100.
  • 63
    McGhie EJ, Hume PJ, Hayward RD, Torres J, Koronakis V ( 2002) Topology of the Salmonella invasion protein SipB in a model bilayer. Mol Microbiol 44: 1309–1321.
    Direct Link:
  • 64
    Marsh D ( 1999) Quantitation of secondary structure in ATR infrared spectroscopy. Biophys J 77: 2630–2637.
  • 65
    Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL ( 1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr Sect D 54: 905–921.
    Direct Link:
  • 66
    Adams PD, Arkin IT, Engelman DM, Brunger AT ( 1995) Computational searching and mutagenesis suggest a structure for the pentameric transmembrane domain of phospholamban. Nat Struct Biol 2: 154–162.
View Full Article (HTML) Get PDF (352K)